^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA M1043I

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
    Entrez ID:
    5290
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    9ms
    A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer (clinicaltrials.gov)
    P2, N=51, Recruiting, GOG Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability)
    |
    PIK3CA mutation • PIK3CA E545 • PIK3CA E542 • PIK3CA M1043I • PIK3CA C420R • PIK3CA N345K • PIK3CA G1049R • PIK3CA Q546
    |
    Piqray (alpelisib) • fulvestrant
    2years
    A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, GOG Foundation | Trial completion date: Apr 2025 --> Apr 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Aug 2024 --> Apr 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability)
    |
    ER positive • PIK3CA mutation • PIK3CA E545 • PIK3CA E542 • PIK3CA M1043I • PIK3CA C420R • PIK3CA N345K • PIK3CA G1049R • PIK3CA Q546
    |
    Piqray (alpelisib) • fulvestrant
    over2years
    Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P2, N=11, Completed, NRG Oncology | Active, not recruiting --> Completed
    Trial completion
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA M1043I • PIK3CA C420R • PIK3CA E545A • PIK3CA N345K • PIK3CA E545G • PIK3CA E545X • PIK3CA G1049R • PIK3CA H1047X • PIK3CA Q546 • PIK3CA Q546K • PIK3CA Q546R
    |
    Aliqopa (copanlisib)
    almost3years
    A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, GOG Foundation
    New P2 trial
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability)
    |
    ER positive • PIK3CA mutation • PIK3CA E545 • PIK3CA E542 • PIK3CA M1043I • PIK3CA C420R • PIK3CA N345K • PIK3CA G1049R • PIK3CA Q546
    |
    Piqray (alpelisib) • fulvestrant
    over3years
    [VIRTUAL] Genomic profiling of esophageal squamous cell carcinoma to reveal actionable genetic alterations. (ASCO 2021)
    Taken together, 17% (20/118) of ESCC patients harbored mutations in the NFE2L2/KEAP1/CUL3 pathway, which may be eligible for clinical trials of glutaminase inhibitor telaglenastat...Furthermore, 11.9% (14/118) patients carried activating PIK3CA mutations including N345K, E542K, E545K, M1043I and H1047R which may be targeted by PIK3CA inhibitor alpelisib... Our findings indicated that amplification of the 11q13 amplicon and dysfunction of the KEAP1-NRF2-CUL3 axis are the major driving events of ESCC . The results of genomic profiling can guide physicians to enroll a significant portion of ESCC patients into genomically matched clinical trials.
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • FGF3 (Fibroblast growth factor 3) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • NOTCH2 (Notch 2) • FGF4 (Fibroblast growth factor 4) • NOTCH3 (Notch Receptor 3) • EP300 (E1A binding protein p300)
    |
    TP53 mutation • HER-2 amplification • PIK3CA mutation • PIK3CA H1047R • PTEN mutation • STK11 mutation • PIK3CA E545K • NF1 mutation • KEAP1 mutation • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • PIK3CA M1043I • PIK3CA N345K
    |
    Onco PanScan™
    |
    Piqray (alpelisib) • telaglenastat (CB-839)